ISRCTN51633881 https://doi.org/10.1186/ISRCTN51633881

A prospective within-patient randomised controlled trial of the treatment of vitiligo with the 308-nm excimer laser: a pilot study

Submission date
12/09/2003

Recruitment status
No longer recruiting

Registration date
12/09/2003

Overall study status
Completed

Last Edited
14/05/2018

Condition category
Skin and Connective Tissue Diseases

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[ ] Results
[ ] Individual participant data
[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr SW Lanigan

Contact details
Department of Dermatology
City Hospital
Dudley Road
Birmingham
United Kingdom
B18 7QH
+44 (0)121 554 3801
Sean.Lanigan@swbh.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0064122126

Study information

Scientific Title
A prospective within-patient randomised controlled trial of the treatment of vitiligo with the 308-nm excimer laser: a pilot study

Study objectives
The main purpose of this study is to determine the efficacy of the 308-nm excimer laser in the treatment of facial vitiligo which is a very cosmetically disabling disorder. This will be a prospective within patient randomised controlled trial and will investigate and quantify the repigmentation achieved with this treatment. We shall also be monitoring the side effects of the treatment if any. The other aspect of the study is to determine if the repigmentation achieved is sustained over a duration of time.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Single centre, patient volunteers, prospective, controlled, therapeutic, observational, single-blind, devices, longitudinal, invasive procedures, randomised study.

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Skin and Connective Tissue Diseases: Facial vitiligo

Interventions
Not provided at time of registration

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
22/04/2003

Completion date
01/06/2005

Eligibility

Key inclusion criteria
17 to 48 patient volunteers will be recruited.

Participant type(s)
Patient

Age group
Child

Sex
Not Specified

Target number of participants
48

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
22/04/2003

Date of final enrolment
01/06/2005

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
City Hospital
Birmingham
United Kingdom
B18 7QH

Sponsor information

Organisation
Department of Health (UK)

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.doh.gov.uk

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Sandwell and West Birmingham Hospitals NHS Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

2004 results in conference proceedings: Bhat J, Ladoyanni E, Lanigan SW: A prospective, within patient, randomised controlled trial (RCT) of the treatment of facial vitiligo with the 308-nm excimer laser. J Eur Acad Dermatol Venereol 2004; 18(suppl 2): 148 FC04.2

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration